HCM
ALDR

Highbridge Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Highbridge Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-216,393
Closed -$7.15M – 1973
2015
Q4 		$7.15M Buy
216,393
+103,467
+92% +$3.5M 0.11% 224
2015
Q3 		$3.7M Buy
+112,926
New +$4.8M 0.06% 377

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Highbridge Capital Management's ALDR Position: Q1 2016 in Review

Highbridge Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q1 2016, closing a stake of 216,393 shares — an estimated $7.15M sold.

Highbridge Capital Management first reported a position in ALDR in Q3 2015 and held it in 2 quarters. The position peaked at $7.15M in Q4 2015. 117 funds tracked by Wall St. Rank hold ALDR as of Q1 2016.

  • Highbridge Capital Management reported no remaining Alder Biopharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 216,393 Alder Biopharmaceuticals shares in Q1 2016, an estimated $7.15M.
  • Highbridge Capital Management first reported a position in Alder Biopharmaceuticals in Q3 2015 and held it in 2 quarters.
  • Highbridge Capital Management's Alder Biopharmaceuticals position peaked at $7.15M in Q4 2015.
  • 117 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2016.

Based on Highbridge Capital Management's 13F filing for Q1 2016, filed 16 May 2016.